傳廣發証券(01776.HK)推離岸人幣計價日息代幣化證券GF Token
《彭博》引述消息人士報道,廣發証券(01776.HK)香港子公司推出以美元、港元及離岸人民幣等貨幣計價的日息代幣化證券GF Token,將可以利用短期閒置資金產生利息,並可用於在其他代幣化資產之間進行轉換。
據悉,GF Token在區塊鏈上發行,並且會在香港持牌加密貨幣交易所Hashkey上進行交易。GF Token只會向機構及專業投資者推銷,美元代幣的基準利率為擔保隔夜融資利率(SOFR),但尚不清楚港元及人民幣代幣的利率。
廣發証券股價今日(27日)高開0.76%,最高見13.9元。近中午收市最新報13.48元,升2.12%,成交916.7萬股,涉資1.24億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.